Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)

v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Total revenues $ 43,979 $ 36,516
Kyprolis    
Disaggregation of Revenue [Line Items]    
Total revenues 17,154 13,432
Kyprolis    
Disaggregation of Revenue [Line Items]    
Total revenues 6,228 4,622
Evomela    
Disaggregation of Revenue [Line Items]    
Total revenues 2,550 2,701
Teriparatide injection    
Disaggregation of Revenue [Line Items]    
Total revenues 3,500 2,911
Rylaze    
Disaggregation of Revenue [Line Items]    
Total revenues 2,609 1,649
Other    
Disaggregation of Revenue [Line Items]    
Total revenues 2,267 1,549
Captisol    
Disaggregation of Revenue [Line Items]    
Total revenues 10,622 12,122
Captisol - Core    
Disaggregation of Revenue [Line Items]    
Total revenues 10,622 6,226
Captisol - COVID    
Disaggregation of Revenue [Line Items]    
Total revenues 0 5,896
Contract revenue    
Disaggregation of Revenue [Line Items]    
Total revenues 16,203 10,962
License Fees    
Disaggregation of Revenue [Line Items]    
Total revenues 114 2,081
Milestone    
Disaggregation of Revenue [Line Items]    
Total revenues 15,300 5,993
Other    
Disaggregation of Revenue [Line Items]    
Total revenues $ 789 $ 2,888